Andrew Komjathy Net Worth

Andrew Komjathy biography

Andrew Komjathy serves as Chief Commercial Officer of the Company. Mr. Komjathy was the Vice President, Commercial Sales at Alkermes, Inc., a publicly held pharmaceutical company, from May 2014 to November 2018. From 2012 to 2014, he was the Vice President, Sales for the U.S. Multiple Sclerosis Business Unit at Genzyme, a publicly held pharmaceutical company. From 2005 to 2012, Mr. Komjathy held three Vice President positions at Shire Human Genetic Therapies, initially as Vice President and General Manager, Commercial Operations in the North American and Asia-Pacific regions, followed by Vice President, Global Franchise Leader for Fabry/Gaucher in Switzerland, and ultimately as Vice President, Commercial Operations. From 1996 to 2005, Mr. Komjathy held positions of increasing responsibility at Biogen. Mr. Komjathy holds an M.B.A. from New York University Stern School of Business and his B.S. in Business Administration from Bucknell University.

How old is Andrew Komjathy?

Andrew Komjathy is 57, he's been the Chief Commercial Officer of Astria Therapeutics Inc since 2019. There are 7 older and 3 younger executives at Astria Therapeutics Inc. The oldest executive at Astria Therapeutics Inc is Michael Kishbauch, 71, who is the Independent Director.

What's Andrew Komjathy's mailing address?

Andrew's mailing address filed with the SEC is C/O CATABASIS PHARMACEUTICALS, INC.,, 100 HIGH STREET, FLOOR 28, BOSTON, MA, 02110.

Insiders trading at Astria Therapeutics Inc

Over the last 9 years, insiders at Astria Therapeutics Inc have traded over $0 worth of Astria Therapeutics Inc stock and bought 3,064,797 units worth $36,777,564 . The most active insiders traders include Jean George, Nicholas Galakatos e Lifesciences Ii, L.P.Clarus.... On average, Astria Therapeutics Inc executives and independent directors trade stock every 0 days with the average trade being worth of $2,617,339. The most recent stock trade was executed by Lifesciences Ii, L.P.Clarus... on 30 June 2015, trading 376,695 units of CATB stock currently worth $4,520,340.

What does Astria Therapeutics Inc do?

Astria Therapeutics Inc executives and stock owners

Astria Therapeutics Inc executives and other stock owners filed with the SEC include:

• Jill Milne,
  President, Chief Executive Officer, Co-Founder, Director
• Joanne Donovan,
  Chief Medical Officer
• Andrew Nichols,
  Chief Scientific Officer
• Kenneth Bate,
  Independent Chairman of the Board
• Michael Kishbauch,
  Independent Director
• Gregg Lapointe,
  Independent Director
• Burt Adelman,
  Independent Director
• Hugh Cole,
  Independent Director
• Joanne Beck,
  Independent Director
• Andrew Komjathy,
  Chief Commercial Officer
• Benjamin Harshbarger,
  Senior Vice President, General Counsel
• Noah Clauser,
  Chief Financial Officer
• Andrea Matthews,
  IR Contact Officer
• Rick Modi,
  Chief Business Officer
• Jean George,
  Director
• V, Llcsv Life Sciences Fund...,
  
• Ron Laufer,
  Director
• Michael Jay Ross,
  Director
• Michael Jirousek,
  Chief Scientific Officer
• Lifesciences Ii, L.P.Clarus...,
  
• Ian C. Sanderson,
  Chief Financial Officer
• Ventures, Inc. Med Immune,
  10% owner
• Nicholas Galakatos,
  Director
• Edward K. Hibben,
  Chief Business Officer
• Fred Callori,
  Director
• Jonathan Violin,
  Director
• Deirdre A. Cunnane,
  Chief Legal Officer
• Advisors Llcperceptive Life...,